- Zacks•4 days ago
Quest Diagnostics Inc. (DGX), a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test.
- Yahoo Finance•6 days ago
Few businesses have as big of a reach in American health care as Quest Diagnostics (DGX). Despite any proposed change to the Affordable Care Act (ACA)—otherwise known as Obamacare—Quest expects to continue its key position in the health care industry, according to CEO Steve Rusckowski. “We’re 2% of health care costs and we determine about 70% of the decisions that are made with health care,” Rusckowski said.
- PR Newswire•6 days agoQuest Diagnostics Launches Nation's First Hepatitis B Virus Quantitative Test to Help Assess Response to Antiviral Therapy
MADISON, N.J., Jan. 18, 2017 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient's response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.2 million individuals infected with HBV. With this insight, physicians are better positioned to monitor response to antiviral medications, and may enable them to modify or adjust treatment to help minimize the likelihood of progression and reactivation.
DGX : Summary for Quest Diagnostics Incorporated - Yahoo Finance
Quest Diagnostics Incorporated (DGX)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||90.50 - 91.21|
|52 Week Range||59.66 - 93.84|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||19.33|
|Dividend & Yield||1.80 (1.98%)|
|1y Target Est||N/A|